Merck’s colorectal cancer therapy fails in late-stage study Reuters

(Reuters) – Merck said on Wednesday its therapy failed to meet the primary endpoint of an late-stage trial evaluating it in patients with a type of colorectal cancer.

The company said patients who took its investigational drug favezelimab in combination with Keytruda did not show a significant improvement in overall survival compared with the standard of care treatment.

Combination therapy is also being evaluated as a treatment for certain blood disorders and solid tumors.